Pharma: Page 26
-
Jackfoto via Getty Images
Biosimilars will gain ground in 2023 with Humira launches — and that’s just the beginning
In Amgen's 2022 Biosimilars Trend Report, the company tracks the progress and potential of the copycat drugs as they reach a pivotal moment.
By Michael Gibney • Oct. 24, 2022 -
Stock via Getty Images
OpinionWhat’s keeping pharma leaders up at night
C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.
By Taren Grom • Oct. 21, 2022 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Mario Tama via Getty Images
J&J reveals just how much economic turbulence is affecting Big Pharma
The healthcare giant showed pharmaceutical gains, but that's no thanks to the economic environment of persistent inflation and a strong U.S. dollar.
By Michael Gibney • Oct. 20, 2022 -
Stock via Getty Images
5 impactful drug trial failures from the last year
Major recent trial flops and what they mean for companies, patients and the industry.
By Meagan Parrish • Oct. 19, 2022 -
Alex Wong via Getty Images
Think your company could be on HHS’ drug price negotiation list? Here’s how to navigate next steps
Know what to expect from the CMS over the next few months as it implements the drug reforms laid out in the Inflation Reduction Act.
By Karissa Waddick • Oct. 18, 2022 -
Stock via Getty Images
A new class of drugs with ‘huge’ potential in the fight against challenging breast cancers
Drug developers have been making headway in treating the most difficult and deadly forms of breast cancer.
By Kelly Bilodeau • Oct. 18, 2022 -
Stock via Getty Images
The Novartis U.S. Foundation’s president on the ‘magical piece’ of its 10-year health equity plan
Dr. Patrice Matchaba discusses Novartis’ end-to-end approach to tackling systemic health disparities.
By Meagan Parrish • Oct. 17, 2022 -
Permission granted by BMS / Ryan Moslin
Q&AHe helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma
Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.
By Michael Gibney • Oct. 17, 2022 -
Stock via Getty Images
OpinionWhat’s your leadership brand?
Pharma industry leaders share their brand personas.
By Taren Grom • Oct. 14, 2022 -
iStock via Getty Images
Q&A // First 90 DaysComing out of stealth, RIGImmune aims to catch up with ever-mutating viruses
President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.
By Kelly Bilodeau • Oct. 13, 2022 -
iStock via Getty Images
Robotic pills could open a world of possibilities for the biologics market
As the oral biologic market heats up, Rani Therapeutics is looking to dominate the field with its robotic pill for treatment of chronic conditions.
By Karissa Waddick • Oct. 13, 2022 -
Permission granted by Ameet Mallik
Q&AWhere the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology
The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.
By Meagan Parrish • Oct. 12, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: HBA’s Nikki Jones
As the Healthcare Businesswomen’s Association’s first chief people and DEI officer, Jones is poised to tackle pay gap inequity, systemic gender bias and leadership barriers impeding women of color.
By Taren Grom • Oct. 12, 2022 -
iStock via Getty Images
The digital therapeutics revolution is happening and Big Pharma is buying in — with caution
Companies like Pfizer, Novartis, Sanofi and BMS are diving into the world of digital therapeutics while recognizing the limitations of the young field.
By Michael Gibney • Oct. 10, 2022 -
Permission granted by GoodRx
Sponsored by GoodRxBeyond buzzwords: Making a practice of diversity, equity and inclusion
Watch Dr. Preeti Parikh, executive medical director at GoodRx, explain how she sees parallels between her mother’s challenges to promote health equity as a physician, and current diversity, equity, and inclusion (DE&I) challenges in the workplace.
Oct. 10, 2022 -
Stock via Getty Images
OpinionAre you a bad boss?
Pharma execs share their tips for being a better leader.
By Taren Grom • Oct. 7, 2022 -
Permission granted by Asia Kepka
Q&AHer antibiotic company failed. Now she’s helping others avoid the same fate.
The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.
By Karissa Waddick • Oct. 6, 2022 -
iStock via Getty Images
Making MovesC-suite shake-ups at 23andMe, Moderna signal new stages of growth
With their latest personnel moves, these life sciences companies are preparing for major business shifts.
By Karissa Waddick • Oct. 5, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Janssen’s Fiona Elwood
The neurodegeneration lead at Janssen is driving precision-based medicine to better understand the pathology of neurological disease for the greatest patient impact.
By Taren Grom • Oct. 5, 2022 -
koto_feja via Getty Images
To stay on the leading edge of oncology, AbbVie knows it has to take risks
In a field that has seen rapid progress but ongoing areas of unmet need, AbbVie is betting on emerging tech.
By Kelly Bilodeau • Oct. 4, 2022 -
Stock via Getty Images
The 2 areas in life sciences most in need of talent
The industry is feeling the hiring crunch — here’s what pharma companies can do to mitigate the impact.
By Meagan Parrish • Oct. 4, 2022 -
Stock via Getty Images
Q&AIt’s electric — speeding up the cell therapy process for scalability
To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.
By Alexandra Pecci • Oct. 4, 2022 -
Marko Georgiev / Stringer via Getty Images
Q&AKeytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut
Long-term results showed five-year survival numbers for lung cancer patients that surpassed all others, and Merck's VP of oncology research tells us what he's excited about.
By Michael Gibney • Oct. 3, 2022 -
Sponsored by Avant Healthcare
The evolving roles and responsibilities of digital opinion leaders in medical education
In the past, patients entrusted their healthcare providers to provide information about health-related matters.
Oct. 3, 2022 -
NanoStockk via Getty Images
Q&AThat’s not Angry Birds — that’s your doctor learning about novel drugs through gaming
How pharma companies can teach physicians about mechanism of action and other medication lessons with interactive mobile games.
By Alexandra Pecci • Sept. 26, 2022
Previous
